CLAIMS

1. Use of an inhibitor compound of type 2 iodothyronine deiodinase (D2) in the manufacture of a medicament for the therapeutic treatment of muscle wasting and/or skin disease and/or muscle disease and/or in a muscle and/or skin regenerative therapeutic method.

2. The use according to claim 1, wherein said inhibitor compound of type 2 iodothyronine deiodinase (D2) is selected from the group consisting of reverse triiodothyronine (rT3), amiodarone (AMIO), dese-thylamiodarone (DEA), 5-methyl-2-thiouracil (MTU), 6-benzyl-2-thiouracil (BTU), xanthohumol (XTH), genistein (GEN), 6-propyl-2-thiouracil (PTU), methimazole (MMI), iopanoic acid (IAc), dexamethasone, gold thioglucose (GTG), and any combination thereof.

3. The use according to claim 1 or 2, wherein said muscle wasting is due to a disease condition selected from the group consisting of sarcopenia, cancer, sepsis, diabetes, chronic heart failure, chronic obstructive pulmonary disease, chronic renal failure, liver cirrhosis, cystic fibrosis, muscle denervation, fasting, and any combination thereof.

4. The use according to claim 3, wherein the disease condition is neoplastic cachexia.

5. The use according to claim 1 or 2, wherein said muscle disease selected from the group consisting of delayed-onset muscle soreness (DOMS), muscular contusion, muscular strain, muscular laceration, cancer cachexia, muscle atrophy, muscle dystrophy, and any combination thereof.

6. The use according to claim 1 or 2, wherein said skin disease is selected from the group consisting of ulcers, dermatitis, skin wounds, burns, lacerations, and any combination thereof.

7. Use of a composition comprising a therapeutically effective amount of at least one inhibitor compound of type 2 iodothyronine deiodinase (D2) as defined in any of claims 1 or 2 and a pharmaceutically acceptable vehicle, excipient and/or diluent, in the manufacture of a medicament for the therapeutic treatment of muscle wasting and/or

skin disease and/or muscle disease and/or in a muscle and/or skin regenerative therapeutic method.

8. The use according to claim 7, wherein said medicament is in a pharmaceutical form for topical, oral, enteral or parenteral administration.

9. The use according to claim 8, wherein the pharmaceutical form for topical administration is selected from the group consisting of cream, ointment, spray, gel, gauze, pad, patch, medicated patch and sponge.

10. The use according to claim 8, wherein the pharmaceutical form for oral administration is selected from the group consisting of tablet, capsule, powder, granule, solution, suspension and syrup.